Royalty Pharma Plc (RPRX) — Long-term Investment Intensity
Royalty Pharma Plc (RPRX) has a Long-term Investment Intensity of 87.8% as of March 2026. Long-term investments of $17.39 Billion represent 87.8% of total assets of $19.82 Billion. A higher ratio indicates a company with significant capital committed to long-duration strategic positions. Check Royalty Pharma Plc liquid asset ratio to evaluate the company's liquid asset resilience ratio.
LT Investment Intensity
Long-term Investments
Total Assets
Country
Royalty Pharma Plc Long-term Investment Intensity (2018–2025)
This chart shows how Royalty Pharma Plc's Long-term Investment Intensity has evolved across 8 annual periods from 2018 to 2025. As of March 2026, the intensity stands at 87.8%, reflecting long-term investments of $17.39 Billion against total assets of $19.82 Billion USD. For the complete balance sheet picture, see Royalty Pharma Plc total assets.
Annual Long-term Investment Intensity for Royalty Pharma Plc (2018–2025)
The table below presents the year-by-year Long-term Investment Intensity for Royalty Pharma Plc from 2018 to 2025, covering 8 annual filings. Each row shows total assets, long-term investments, the intensity percentage, and the change in percentage points compared to the prior year. Read RPRX current and long-term liabilities for a breakdown of total debt and financial obligations.
| Year | LT Investment Intensity | LT Investments (USD) | Total Assets | Change (pp) |
|---|---|---|---|---|
| 2025 | 87.1% | $17.09 Billion | $19.62 Billion | ▼ -2.8 pp |
| 2024 | 89.9% | $16.39 Billion | $18.22 Billion | ▼ -2.3 pp |
| 2023 | 92.2% | $15.10 Billion | $16.38 Billion | ▲ +8.2 pp |
| 2022 | 84.0% | $14.12 Billion | $16.81 Billion | ▲ +2.0 pp |
| 2021 | 82.0% | $14.36 Billion | $17.52 Billion | ▲ +20.5 pp |
| 2020 | 61.5% | $12.97 Billion | $21.10 Billion | ▼ -30.7 pp |
| 2019 | 92.2% | $11.48 Billion | $12.45 Billion | ▲ +16.0 pp |
| 2018 | 76.2% | $8.67 Billion | $11.37 Billion | — |